pAtient rePorted Outcomes Linked With histoLogy in Patients With uLcerative cOlitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

86 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-07-01

Study Completion Date

2021-07-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background and rationale:

In ulcerative colitis, treating beyond endoscopic healing has shown a reduction of relapse and hospitalization, pushing for histological remission in daily clinical practice.1 However, very little is known on how histological remission is associated with patient reported outcomes (PROMs).2,3 In recent years, several questionnaires have been developed to assess what really matters to patients: symptoms and the burden UC exerts on them.4 As PROMs are getting more and more attention during drug development programs and drug approval by international organizations, including FDA and EMA, the link between objective outcome measures (endoscopic, histological, biochemical) and PROMs should therefore be better characterized.

Objectives and design:

To investigate prospectively the association of patient reported outcomes (PROMs) and biochemical, endoscopic and histological outcome measures in patients with ulcerative colitis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison Between Bowel Ultrasound-based Treat to Target Versus Routine Treat to Target Strategies in Ulcerative Colitis

NCT05735665

Ulcerative Colitis Chronic Moderate Ulcerative Colitis Chronic Severe

UNKNOWN NA

Remote Monitoring of IBD

NCT05886322

Inflammatory Bowel Diseases Crohn Disease Ulcerative Colitis

UNKNOWN

Hematological Indices and Fecal Calprotectin Predict Histological Remission in Ulcerative Colitis

NCT04818788

Ulcerative Colitis

UNKNOWN

Assessment of Disease Activity in Ulcerative Colitis by Endoscopic Ultrasound

NCT01852760

Ulcerative Colitis Inflammatory Bowel Disease

COMPLETED

Multimodal Ultrasound in Inflammatory Bowel Diseases

NCT05987501

Inflammatory Bowel Diseases

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After informed consent, patients will undergo endoscopic assessment evaluating endoscopic disease activity using established scoring systems

* Mayo endoscopic sub-score5
* Ulcerative Colitis Endoscopic Index of Severity \[UCEIS\]6 All endoscopic assessments will be recorded, allowing blinded scoring by independent endoscopists afterwards. Study protocol APOLLO - 2 During endoscopy, colonic biopsies will be taken according to standard of care from the most inflamed area of the colon and normal area if applicable, 0-60cm from the anal verge. All biopsies will be scored histologically using the Nancy Index.7 During the same study visit, clinical symptoms (Simple clinical colitis activity index \[SCCAI\]) and patient reported outcomes (PROMs) will be evaluated digitally using validated scoring systems8
* IBD disk
* PRO-2
* Visual Analogue Scale
* IBD control in case of non-remission Finally, patients will be biochemically (C-reactive protein, hemoglobin, albumin) evaluated, including measurement of drug level (infliximab, adalimumab, vedolizumab) in case of ongoing exposure to biological agents. All evaluations are part of standard-of-care. Definitions
* Endoscopic remission: Mayo endoscopic sub-score 0 AND UCEIS 0
* Endoscopic response according to

* Mayo score: decrease in Mayo endoscopic sub-score ≥ 1
* UCEIS: decrease in UCEIS ≥ 2
* Endoscopic improvement: Mayo endoscopic sub-score 1
* Histological remission: Nancy histological index 0
* Absence of active/acute histological inflammation: Nancy histological index 0-1
* Histological response: Nancy histological index \> 1
* PRO2 remission: stool frequency ≤ 1 (absolute stool frequency ≤ 3 OR 1-2 stools more than usual) AND rectal bleeding score of 0 (average of 3 days prior to endoscopy)
* IBD disk remission per item:

* Abdominal pain
* Regulating defecation
* Interpersonal interactions
* Education and work
* Sleep
* Energy
* Emotions
* Body Image
* Sexual function
* Joint pain

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ulcerative Colitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients with ulcerative colitis

patients with ulcerative colitis and planned endoscopy as part of routine care

endoscopic biopsies

Intervention Type DIAGNOSTIC_TEST

patients with planned endoscopy for ulcerative colitis have endosocpic data recorded aswell as biopsy sampling and blood tests

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

endoscopic biopsies

patients with planned endoscopy for ulcerative colitis have endosocpic data recorded aswell as biopsy sampling and blood tests

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All patients with ulcerative colitis (≥ 16 years) undergoing planned endoscopic assessment as part of standard of care between 01.07.2020 and 30.06.2021. Evidence of a personally signed and dated informed consent document (ICF) indicating that the subject has been informed of all aspects of the study.

Exclusion Criteria

Subjects with a diagnosis of indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis, microscopic colitis or Crohn's disease.

Subjects with clinical findings suggestive of CD (e.g. fistulae, granulomas on biopsy) are also excluded. Similar data collection within 8 weeks prior to endoscopic assessment

Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No